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Diabetes mellitus is defined by a group of metabolic 
disorder caused by altered metabolism of carbohydrate, 
lipid and lipoprotein resulting from the defect in insulin 
secretion and action; it is characterized by symptom 
likehyperglycemia, glycosuria, polyphagia, polyurea, 
polydipsia, gradual loss of weight, fatigue, cramps, blurred 
vision, constipation, and candidiasis are prominent.It is the 
most prevalent chronic disease in the world affecting 
nearly 100 million persons of the population where 5-10% 
having type 1 while 90-95% of them suffers from type 2 
diabetes mellitus.Diabetes leads to many health 




Categorization of Diabetes 
There are mainly four types of diabetes mellitus i.e. Type I 
diabetes or insulin dependent diabetes 
mellitus(IDDM),type II diabetes or non insulin dependent 
diabetes mellitus (NIDDM),the other two diabetes mellitus 
are not much common i.e. gestational diabetes and 
genetically modified diabetes 
4
. Type I diabetes can occur 
in any age but priorly seen in young adult. It is an immune 
mediated disease resulting from destruction in β-cells of 
pancreas which leads to insufficientendogenous insulin 
production. Type II diabetes or non insulin dependent 
diabetes mellitus (NIDDM) is the most common type  
affecting elderly and obese personcaused either by insulin 
resistance or deficient insulin secretion.It is characterized 
by hyperglycemia in the presence of hyperinsulinemia due 
to peripheral insulin resistance. Type 2 diabetes mellitus is 
most encountered form of diabetes accounting for more 
than 80% of total case of diabetes while in western 
countries it affects 7% of the population in particular
5
.A 
third type of diabetes  GDM (gestation diabetes mellitus) is  
first recognize during pregnancy where hyperglycemic 
condition developsin women who doesn’t have diabetes 
result from an inadequate insulin supply to meet tissue 
demand for normal blood glucose regulation. Fourth type 
of diabetes is genetically modified DM there occur defects 
in β cell function or mutation of insulin receptor and may 
lead to diabetes. Other rare types of diabetes include those 
caused by surgery, drug used (e.g. antihypertensive 
vasodilator diazoxide, corticosteroids in high doses, lower 
dose of thiazides, oral contraceptives, high dose of 
anabolic androgens,  streptozotocin, alloxan, theophylline, 
asprin, isoniazid, nalidixic acid ), malnutrition, infection 
and other illness. 
6
 
Acute and long-term occurrence of type 1 and type 2 
diabetes mellitus can result in macrovascular (coronary 
artery disease, atherosclerosis and peripheral vascular 
disease) and microvascular (retinopathy, nephropathy, and 
neuropathy) complications 
7
. Chronic hyperglycemia is an 
important factor leading to complications of DM causing 
diverse cellular and organ dysfunctionwhich may lead to 
autonomic dysfunction, potential blindness, renal failure 
(due to nephropathy), and foot ulcers, amputation, Charcot 
joints (due to neuropathy).  
Insulin and its secretion 
The insulin is a polypeptide hormone having a molecular 
weight of 6000 Da. It is originally produced as a single 
molecule (pre-proinsulin) consists of 110 amino acids 
released by the pancreatic β-cells whichareresponsible for 
glucose homeostasis. It consists of two polypeptide chains 
A and B containing 21 and 30 amino acid residue 
respectively.
8
Two disulfide bridges (residue A 7 to B7 and 
A20 to B19) covalently bind the chain where chain A 
containsan internal disulfide bridge (residue A6 to A 
11).Hormone insulin is synthesized as pre- proinsulin in 
rough endoplasmic reticulum further by proteolysis it 
convert to pro-insulin and then to insulin.The A chain has 
an amino terminal helix (A1 –A8) linked to an anti-parallel 
carboxy- terminal helix (A 12-A20). The B chain has a 
central helix (B8-B19), flanked by extended amino and 
carbonyl terminal strands. This arrangement is called the T 
conformation. .After pre-proinsulin has passed through the 
endoplasmic reticulum, 24 amino acids are removed by 
enzymatic action from one end of chain, leaving another 
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form pro-insulin that undergoesfolds and bonds to passes 
towardsGolgi body where the middle section (C chain) of 
33 amino acids is removed by the action of the enzymes 





Figure 1: Insulin structure showing its disulfide bridge, its hexameric structure and describing its A and B chain 
with its amino acid sequence 
Insulin stimulates hepatocytes, mycocytes and adipocyte to 
uptake glucose for circulatory system. Insulin is needed to 
move blood glucose into cell where it stored (and 
depending on the need glucose can either be stored as 
glycogen inside muscles or liver cells. The inappropriate 
utilization of insulin leads to insulin resistance, which is 
characterized by inability of cells to respond to normal 
level of circulating insulin, thus leads to occurrence of 
disease. Histologically there is not much difference in islet 
of diabetic pancreas and the normal pancreas apart from 




Figure 2: Insulin Releasing Pathway 
The insulin release is a complex process involving the 
integration and interaction of multiple external and internal 
stimuli. Glucose is mediated into the β cell with the help of 
GLUT- 2 for the glycolysis (energy producing pathway). 
Glucose is further phosphorylated with the help of 
glucokinase enzyme and further metabolized to form ATP. 
Elevation in ATP ADP ratio causes the ATP-gated 
potassium channels in cellular membrane to close, 
preventing potassium ions from being shunted across the 
cell membrane. This increase intracellular conc. of 
potassium ions lead to depolarization of cell. This in turn 
activates the voltage gated calcium channel and facilitates 
extracellular calcium influx into the β cell. Ultimately by 
the process of exocytosis insulin is exported from the 
insulin storing granules and diffuses into nearby vessels. 
Insulin is the sole therapy currently available to treat acute 
hyperglycemia. It’s have multiple metabolic and cellular 
actions firstly it lowers plasma  glucose level, along with 
that it helps in maintaining normal cell metabolism by 
increasing glucose uptake and adenosine triphosphate 
(ATP) production in by glycolysis. Insulin provides 
protection from endothelial dysfunctioning, inflammation 
(by reducing levels of proinflammatory cytokines, 
adhesion molecule) and thrombosis.  Insulin injections is 
effective in T2DM for controlling blood sugar  prescribed 
when glucose target cannot be attained with standard 
regimen, it causes weight gain specifically abdominal fat 
which can lead to insulin resistance and various 
cardiovascular risk. 
Hypoglycemic Drugs 
Anti-diabetic drug acts through two main mechanisms by 
stimulating β-cells of pancreatic islet to release insulin and 
increase the sensitivity or number of insulin receptor. 
Preoperatively, oral hypoglycemic agents, especially those 
that stimulate insulin secretion, such as sulfonylureal and 
meglitinide agents, have potential for producing 
hypoglycemia during fasting prior to surgery. 
The sulfonylurea agents (e.g. glipizide, glyburide, 
glimepiride) are commonly prescribed oral hypoglycemic 
agents for the treatment of type 2 diabetes. These agents 
act by bind to the ATP-dependent potassium (KATP) 
channel in the pancreatic s-cells, leading to closure of 
these channels and stimulating insulin release. Thus, 
pancreatic β-cells are increasingly responsive to glucose 
concentrations and insulin release is augmented. 
Metformin, a biguanide oral hypoglycemic agent, is 
commonly used for treatment of type II diabetes mellitus. 
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Metformin primary mode of action appears to be that of 
increasing hepatic insulin sensitivity, resulting in 
decreased hepatic glucose output through suppression of 
gluconeogenesis and glycogenolysis. 
16
. Sulfonylurea and 
metformin are used although they have several side effects 
(weight gain, hypoglycemia) because they are cost 
effective.α-glucosidase inhibitors are another class of 
drugs that includes compound like acarbose which delay 
the intraluminal production of monosaccharide (glucose). 
Acarbose competitively inhibits α-glucosidase that is 
associated with the brush border membrane of the small 
intestine and are responsible for the digestion of complex 
polysaccharides and sucrose. This slows carbohydrate 
digestion and lowers post-prandial hyperglycemia. 
Biguanides (metformin), suphonyl urea, thiazolidine and 
meglitinides are the main class of drugs used in diabetes 
they have various side effects like weight gain, lactic 
acidosis, heart failure and hepatotoxicity which will lead to 
other serious complications.Natural compounds may be 
analternative treatment as they can be included in daily 
diet and can be taken in larger amount without any risk. 
Many plants areknown in folk medicine of different 
culture to be used for their antidiabetic property. The plant 
and biomolecule have been reviewed for prophylaxis and 
treatment of type 2 diabetes. 
Recent advancement in Diabetes treatment 
Rimonabant is first drug which act through 
endocannabinoid system (ECS) that play an important role 
in appetite and carbohydrate and fat metabolism in brain as 
well as adipose tissue. Animal studies show that it acts 
through blocking the ECS leading to weight loss and 
improve insulin sensitivity by reducing the level of 
adiponectin. It result in weight loss, improve insulin 
release and sensitivity and suppresses appetite andacts by 
blocking CB 1and CB 2receptor
14
.  
Exenatide, a synthetic version of Exendin-4a peptide 
discovered in the salivary secretions of the reptile 
Heloderma suspectum.  Exenatide belongs to GLP 1 class 
that plays an important role in weight loss and as seen in 
animal studies it act by HbA1c reduction. Exeratide 
resulted in a hemoglobin A1c (HbA1c) reduction reduction 
of 1.0% with placebo treatment.It is used with metformin 
and sulfonyl urea alone or in combination.
15
 
Sitagliptin, a DPP- IV inhibitor   it hypoglycemic action is 
due to increase in GLP 1 and GIP level. It act by 
suppressing appetite it target prandial and fasting glucose 
level, improve marker of β cell function. Vildagiptin also 




Another new anti- hyperglycemic used in T1DM is the 
injectable pramlintide(amylin mimetics), a synthetic 
analogue of human amylin, a β cell peptide cosecreted 
with insulin act as. It suppresses glucagon secretion from 
pancreatic α cells, thereby attenuating glucose production. 
RYpramlintide in T2DM is not so clear. Liraglutide is an 
acrylated human GLP 1 analogue while is nearly identical 
to it with lysine 34 to argentine substitution ans an addition 
of a C-16 free fatty acid derivative at lysine 26. The free 
fatty acid side chain promotes binding to albumin and 
other plasma proteins leading to delayed absorption rate 
from the injection site and extended plasma half life of 11-
13 h. Dapagliflozin anew drug for treatment of T2DM 
aims to lower blood sugar by improving glycemic control 
independent of insulin action. The drug reduces renal 
glucose reabsorption and increases glucose elimination in 
urine. 
A Scottish medicine consortium have work on lixisentide 
(brand name Lyxumia) a short-acting GLP-1-receptor 
agonist is a modified exerdin 4 base molecule with 2-4 hr 
short half life it shown beneficial effects on HbA1c when 
combined with commonly used anti-diabetic agents on the 
health care service to people suffering from T2DM, studies 
shows that adding lixisenatide to insulin or taking it with 
other glucose lowering medicine controlled patient 
diabetes and also reduction in body weight.A series of 
clinical trials with 5000 participants began in May 2008. 
Results showed that lixisenatide was well-tolerated, with 
mild nausea and vomiting being the most common side 
effects.It is recommended for patients whose existing 
treatments, combined with a calorie-controlled diet and 
exercise; do not provide adequate glycemic control. By 
maintaining blood sugar level as near to normal as possible 
is vital to reduce the risk of long term complications such 
as heart disease, blindness, strokes and kidney failure. 
Gemingliptin is another DPP4 that has been approved by 
the Korean food and drug administration on june 2012 as a 
treatment for T2DM patient and is under phase III clinical 
trial to be approved by US FDA for its safety and efficacy. 
Herbal remedies for treatment of diabetes 
Plants have been a good source of drugs. There are more 
than 800 plants that possess potent anti-diabetic activity 
and have been used as a dietary adjuvant or as a drug 
which have a traditional history in India. This treatment is 
the safe, cost effective and with least of side effect than 
that of synthetic hypoglycemic agent. The plant originated 
products act through two mechanism either 
insulinomimetic or as secretagogues. There are various 
types of phytoconstituents like alkaloids, flavonoids and 
saponins glycosides present in the plants responsible for its 
anti-diabetic activity.. Alkaloids acts by inhibiting α –
glucosidase and decrease glucose transport through 
intestinal epithelium. Flavanoids suppresses glucose level, 
reduces plasma cholesterol and triglyceride significantly 
and increases hepatic glucokinase activity probably by 
enhancing insulin from β cells. 
Achyranthes aspera L produced a significant dose-related 
hypoglycemiceffect in normoglycaemic in alloxan-induced 
diabeticrabbits. In these animals, water and methanol 
extracts alsodecreased blood sugar levels.
21
 
Aloen(A.barbidensis) leaves orally (500mg/kg) along with 
its bitter principle(5 mg/kg) .i.p. was very highly 
significant in reducing plasma glucose level and significant 
effect was seen within 5 days it work by stimulating 
synthesis and release of insulin from cell of langerhans 
22
. 
Andrographis paniculata results in significant reduction of 
blood glucose compare to un-treated it acts by inhibiting 
glucose absorption. Aronia melenocarpa berries possess 
numerous biological and medicinal effects
23
 they are rich 
in phenolic antioxidants, especially anthocyanins. Their 
fruit juices have significant effect on plasma glucose and 
lipid level in streptozotocin induced diabetic rat.it act by 
lowering triglyceride level 
24
. 
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Artemisia dracunculus L. has been reported to have hy-
poglycaemic effects by several researchers 
25, 26
. Wang et 
al.found that Artemisia dracunculus L. improved insulin 
sensitivity and IR signaling in insulin-resistant KK-Ay 
mice models. 4,5-di-O-caffeoylquinic acid, 6-
demethoxycapillarisin, and 2’,4’-dihydroxy-4-methoxy-
dihydrochalcone was extracted from the ethanolic extract 
of Artemisia dracunculus L.
27
 The compounds showed 
inhibitory effects towards the enzyme aldose reductase 
(enzyme involved in diabetic complications), which may 
explain the antidiabetic effect. Oral administration of 
extract of Asteracantha longifolia (20 g/kg of starting 
material) can significantly improve glucose tolerance in 
healthy human subjects anddiabetic patients. Dried Allium 
cepa when extracted in petroleum ether control diabetes in 
alloxan induced diabetes rat. 
Azadirachta indica has been used in ayurvedic medical 
tradition as a treatment for diabetic mellitus its in-vivo 
antidiabetic activity was seen in streptozotocin-
nicotinamide induced diabetes mice. It contains 
meliacinolin; apotent α-Glucosidase and α-Amylase 
inhibitor 
28
 which reduces oxidative stress and act as an 
insulogenic. It acts by inhibiting glucose absorption. 
Anemarrhena asphodeloides exhibits antidiabetic effect in 
streptozotocin induced mice model. It contain 
prototimosaponin A-III and pseudo-prtotimusaponin A –III 
they act by inhibiting hepatic glyconeogensis and 
glycogenolysis. 
Ethanolic extract of the root part of Bambusa arundinacea 
(Poaceae) was evaluated for its hypoglycemic potential in 
normoglycemic rats followed by alloxan and glucose 
loaded hyperglycemic rats by single dose and multidose 
administration; the plant extract significantly reduces 
blood glucose level both in normoglycemic and 
hyperglycemic rats induced by alloxan and oral glucose 
loaded methods till the end of the course of experiment. 
The preliminary phytochemical study report revealed that 




Hot water extract of Bixa orellana plant have potent 
inhibitory activity toward rat lens aldose reductase 
30
.Bougainvillea spectabilis leaves oral administration 
significantly lowers hyperglycemic response in alloxan- 




Seeds of Coriandrum sativum L(Coriander), when 
supplied in the diet (6.25 % by weight) and infusion (1 
g/400 ml) in place of drinking, reduced the hyperglycemia 




In a study conducted over type 2 diabetic mice, 
administration of Curcuma longa L. rhizomes extract led 
to the activation of the peroxisome proliferator-activated 
receptor-γ (PPAR-γ) 33 through the ligand binding activity 
of the extract towards the receptor. PPAR-γ is a key recep-
tor in lipid and glucose homeostasis because of its ability 
to reduce the plasma free fatty acids (FFAs) 
34, 35
. The 
receptor is currently used as a target for the treatment of 
T2DM 
36
; the antidiabetic thiazolidinediones drugs exert 
their insulin sensitizing action through their high affinity 
for the receptor PPAR-γ. Thus, Curcuma longa is a 
promising therapeutic agent in the prevention and/or 
amelioration of T2DM. Lee et al. (2008) tested a combined 
hypoglycaemic mixture of Melissa officinalis L., Morus 
albaL., and Artemisia capillaris Thunb that resulted in 
changes in the expression of the PPAR-α, another key 
receptor in lipid and lipoprotein metabolism
37
. By 
conducting in vitro experiments on rat pancreatic β-cells 
using Cornus officinalis extracts, Chen et al. (2008) found 
that the extracts possessed insulin-mimetic activity and 
stimulated β-cell function by enhancing insulin secretion 
and protecting β-cells against toxic damage 38, 39. 
Daucus carota L extractwas prepared by boiling the dried 
material with water or macerating it with 80 % ethanol. It 
was shown that the extract improved the glucose tolerance 
40
. 
Emblica officinalisfruits and seed extractedin different 
solvent act as α- amylase and α- glucosidase inhibitors 
have significant hypoglycemic activity
41
. Ficus 
bengalensis (banyan tree) result in significant decrease in 
blood and urine sugar level, certain lipid content in serum 
42
. Fructus arctii was investigated to its hypoglycemic 
activity in alloxan induced diabetic mice amd 
hyperglycemic hyperlipidemic diabetic rats. It shows 
significant reduction in plasma glucose, triglycerides and 
total cholesterol after treatment with total lignin from 
plant. 
Hibiscus vitifolious flower petals contain 3, 4, 6, 8 
tetrahydroxy flavonol -5- (-methyl ether 7-0 
neosperidoside) which as an active compound having 
hypoglycemic activity well demonstrated in albino rats
43
. 
Ginseng Radix (GR) to normal and adrenaline-induced 
hyperglycemic mice caused a significant decrease in blood 
glucose level 4 h after its administration. The hepatic 
content of the facilitative glucose transporter isoform 2, 
liver type glucose transporter (GLUT 2) protein 
significantly increased in the orally GR-treated healthy and 
adrenaline-induced hyperglycemic mice compared to that 
in the controls. Recently, ginseng, which is among five 
crude drugs included in the traditional Chinese 
prescription, Byakkoka- ninjin-to, was investigated using 
genetically obese diabetic KK-CA(y) mice and alloxan-
diabetic mice
44
. The water extract of ginseng, when 
individually tested, markedly lowered blood glucose level 
in diabetic animals. 
Holarrhena antidysentrica bark aqueous and alcoholic 
extract reduces the blood sugar level in normal and alloxan 
-induced diabetic rats
45
. Inula racemosa root petroleum 
extract result in lowering plasma insulin and glucose level 
when administered in adrenaline –induced hyperglycemia 
in albino rats. 
46
 
Juniperus communis lowers the glycemic level by 
increasing peripheral glucose consumption and 
potentiation of glucose induced insulin secretion. 
Lagerstroemia specisoa showed slow glucose activity. 
Momordica charantia ethanolic extract decreases blood 
sugar in normal and diabetic rat model. Morinada lucida 
aqueous extract have potent hypoglycemic effect in 
normoglycemic and alloxan induced diabetic mice. 
Momordica dioica fruit ethanolic and ethyl acetate extract 
has been found to have hypoglycemic activity when 
studied in alloxan induced diabetic rat which was due to 
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presence of steroids, triterpenoids and their 
glucoside
48
.Nymphaea pubescens ethanolic extract have 
significant activity in reducing blood glucose when study was 
conducted on diabetic rat histopathological examination of 
pancreas shows regenerative potential corroborating its anti 
diabetic potency. Nicotiana glutinosa leaves contain sucrose 
fatty acid compounds which are helpful in treatment of 
disease associated with diabetes.
49, 50, 51
 
Ocimum sanctum alcoholic extract led to mark reduction of 
blood sugar in glucose fed hyperglycemic and streptozotcin 
induced diabetic rat. Ocimum gratissimum methanolic extract 
have shown lowers the blood glucose level in diabetic male 
wistar rat 
52
. Papaver somniferum extract seed extract when 
given orally reduces blood glucose level in alloxan induced 
diabetic rats. Paspalum scrobiculatum aqueous and ethanolic 
extract reduces blood glucose level and lipid parameters in 
diabetic rats. Methanolic extact of Phyllantus amarus was 
found to have potent anti diabetic activity and it also inhibits 
lipid peroxidation and reduces blood sugar level in diabetic 
rats.Scoparia dulcis and Scopari adulcis extractsignificantly 
reduces lipid peroxidation and possess anti diabetic activity 
and are widely used in Indian folk medicine. Sephaernthus 
indicus flower head petroleum ether extract anti diabetic 
activity was studied in alloxan induced diabetic wistar rat by 
reducing blood glucose level 
54
. 
Terminalia chebula, Emblica officinalis and Terminalia 
belerica combination named triphala (equal portion of all the 
three) are found to inhibit lipid peroxidation and scavenge 
hydroxyl and superoxide free radical in vitro. Oral 
administration of the extract reduces the blood sugar level in 
normal and alloxan induced diabetic rats.  Tinospora 
cordifolia stem extract significantly lowers blood glucose 
level, reduce glycosylated hemoglobin level, reduced 
glucokinase and increases G6-P activity. And along with that 




Trigonella foenum-graecum(fenugreek) seeds contains 
alkaloid trigonelline that counterected to hyperglycemic effect 
of cortisone in non diabetic rabbit by lowering blood glucose 
capacity. Other hypoglycemic compound present in the seeds 
are nicotinic acid, coumarin, and scopletine
53
. 
Vernonia amygdalina aqueous extract when given 
intraperitoneally produces a dose related fall in blood glucose 
when compared it effect along with tolbutamide by enhancing 
insulin secretion. 
Zaleya decandra root ethanolic extract significantly restore 
the level of glucose, Total cholestrol, Triglycerides, Total 
protein, urea, cretinine , lipid peroxidation level and 
antioxidant enzyme when histopathological studies was 
conducted on alloxan induced diabetic rats
54
.  
Management of disease  
Diabetes mellitus requires multidisciplinary approach for the 
management. It requires proper diet monitoring, exercise and 
stress management as a non-pharmacological approach.  
 A proper monitoring of diet is needed for diabetic patient. In 
type I and II DM caloric distribution of energy should be 55-
60% carbohydrate, 10-15% protein and 20-25% from fat. 
Calories intake should be monitored by restricting diet. Fiber 
rich food should be included in the diet specially cellulose or 
hemicelluloses which are having beneficial effect on intestinal 
transit time and thereby slow down glucose absorption thus 
decreasing hyperglycemia. Fruits should be taken in moderate 
while very sweet fruits should be avoided. Fish oil has been 
reported for beneficial omega 3 which plays important role in 
reducing plasma triglycerides and lipoproteins level.  Along 
with that alcohol and tobacco should be avoided. Artificial 
sweetener like saccharin and aspartame are advised in 
replacement of sugar. Further there is evidence that regular 
exercise and yoga can reduce the risk of obesity and further 
helps in controlling diabetes.  
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